Obiltoxaximab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Objective: To review the safety and efficacy of obiltoxaximab, a monoclonal antibody indicated for the treatment of Bacillus…
Inhalational anthrax is a highly lethal infection caused by Bacillus anthracis and a serious bioterrorism threat. Protective…
ABSTRACT The recommended management of inhalational anthrax, a high-priority bioterrorist threat, includes antibiotics and…
Obiltoxaximab (Anthim®, ETI-204) is a monoclonal antibody that is being developed by Elusys Therapeutics and the US Department of…
ABSTRACT The Centers for Disease Control and Prevention recommend adjunctive antitoxins when systemic anthrax is suspected…
ABSTRACT Inhalational anthrax has high mortality even with antibiotic treatment, and antitoxins are now recommended as an adjunct…
Obiltoxaximab, a monoclonal antibody against protective antigen (PA), is approved for treatment of inhalational anthrax under the…
A new agent used to treat and prevent inhalational anthrax has received FDA approval.
Obiltoxaximab, marketed as Anthim, is…